# Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-generating-clinical-evidence-from-oncology-multiregional-clinical-development-programs/78fa8deb-dab7-4321-a08d-f5971e107619

> FDA guidance document: Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs. Issue date: September 16, 2024. Get complete insights and analysis.

---

## Details

- Title: Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2024-09-16
- Comment Close Date: 2024-11-18
- Last Changed: 2024-09-16
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-3163">FDA-2024-D-3163</a>

## Related Documents

- [Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f)
- [Considerations in Demonstrating Interchangeability With a Reference Product: Update](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-update/f154845a-a15e-4508-a634-dd22f907a286)
- [Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics/adf9cb72-5955-4d5f-8f26-4e226281ace9)